I have completed some initial research on Venetoclax in relapsed...

I have completed some initial research on Venetoclax in relapsed or refractory (R/R) acute myeloid leukemia. At first blush, it has an overall response rate of 19% and a tolerable safety profile. However in some small trials it appears to have better response rates for IDH1/2-mutant r/r AML (25%) and RUNX1-mutated (50%). Note the different variants of AML respond better or worse to various treatments, presumably this is also going to be true for Bisantrene (this variation in the historical trials).

Note there are some ongoing studies to evaluate response rates further: https://clinicaltrials.gov/ct2/show/NCT03441555 https://clinicaltrials.gov/ct2/show/NCT03625505 https://clinicaltrials.gov/ct2/show/NCT03404193

I expect similar combination trials would be run with Bisantrene and other drugs, even between Venetoclax and Bisantrene. In short let's not throw the baby out with the bath water here folks.